Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
Subscribe To Our Newsletter & Stay Updated
